BTM signed esxclusive rights to commercialize new three products in China, supplement its Orthopedic product portfolio and entering the treatment in rare disease

Osteoarthritis treatment is the 3rd largest treatment market in the world only after the treatment for malignant tumor and diabetes. The number of osteoarthritis patients in China has reached 140 million. Through cutting-edge patented technology, BTM001 and BTM002 provide joint recovery therapy for clinical use and can meet the needs of patients with joint diseases such as long-term pain relief, recovery of knee joint flexibility, etc. Through introducing the products, BTM has preliminary formed an Orthopedic product porttfolio with unique clinical treatment features.

Interstitial cystitis is a Chronic Painful Bladder Syndrome based on frequent urination, urgent urination, bladder or pelvic pain. It is a rare disease which mostly affects women aged from 30 to 50. The morbidity in China is estimated at 40 per 100,000 people. Although the disease has been known for a century, its etiopathogenesis is still unclear and there is no effective treatment. BTM003 can effectively relieve bladder pain or discomfort caused by interstitial cystitis. It is also BTM’s first product following its development strategy to penetrate into the field of rare disease treatment. BTM will continue to introduce innovative drugs for the treatment of cystitis and other rare diseases.